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Abstract
[C17H17F6N2O][C2F3O2], triclinic, P1¯ (no. 2), a= 7.9873(1) Å,
b= 11.0534(2) Å, c= 13.2380(3) Å, α= 105.617(1)°,
β= 102.189(1)°, γ= 106.075(1)°. V = 1028.76(3) Å3, Z= 2,
Rgt(F)=0.0403, wRref(F2)=0.1086, T= 120(2) K.
CCDC no.: 1895037
The title crystal structure is shown in the figure. Tables 1
and 2 contain details on crystal structure and measurement
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Table 1: Data collection and handling.
Crystal: Colourless slab
Size: 0.44×0.26×0.18 mm
Wavelength: Mo Kα radiation (0.71073 Å)
µ: 0.16 mm−1
Diffractometer, scan mode: Bruker-Nonius Roper, φ and ω
θmax, completeness: 27.5°,>99%
N(hkl)measured, N(hkl)unique, Rint: 21617, 4704, 0.029
Criterion for Iobs, N(hkl)gt: Iobs > 2 σ(Iobs), 4151
N(param)refined: 307
Programs: SHELX [1–3], WinGX/ORTEP [4],
COLLECT [5] and DENZO [6]
conditions and a list of the atoms including atomic coordi-
nates and displacement parameters.
Source of material
Solutions of mefloquine (0.38 g, 1 mmol) in ethanol (10 mL)
and trifluoroacetic acid (0.13 g, 1.3 mmol) in ethanol (10 mL)
weremixed and refluxed for 20 min.On leaving the open reac-
tion mixture at room temperature, colourless crystals were
collected after 4 days. M.pt: 503−505 K. 1H NMR (400 MHz,
d6-DMSO): δ: 1.18−1.32 (2H, m), 1.57−1.80 (4H, m), 3.00−3.10
(1H,m), 3.30−3.38 (1H, br, d), 3.47−3.67 (1H, br, d), 5.96 (1H, s),
6.23 (1H, br, s), 7.10 (1H, s), 7.94 (1H, t, J= 8.0 Hz), 8.14 (1H, s),
8.33 (1H, d, J= 8.0 Hz), 8.75 (1H, d, J= 8.0 Hz) ppm. 13C NMR,
d6-DMSO): δ: 21.38, 21.38, 21.79, 44.71, 59.18, 68.08, 115.68,
117.24 (q, JC,F= 296 Hz), 121.38 (q, JC,F= 274 Hz), 123.81 (q,
JC,F= 272 Hz), 126.59, 127.55 (q, JC,F= 29.4 Hz), 128.31, 128.91,
129.86 (q, JC,F= 4.7 Hz), 143.05, 147.03 (q, JC,F= 34Hz), 151.25,
159.59 (q, JC,F= 32 Hz) ppm. 19F NMR (d6-DMSO): δ: −59.2,
−67.0,−74.1 ppm.
Experimental details
The C-bound H atoms were geometrically placed (C—
H=0.95–1.00 Å) and refined as riding with U iso(H)= 1.2–
1.5Ueq(C). The O- and N-bound H atoms were located in a dif-
ference Fourier map andwere refinedwith distance restraints
of O—H=0.84 ± 0.01 and N—H=0.88 ± 0.01 Å, respec-
tively, and with U iso(H) set to 1.5Uequiv(O) and 1.2Uequiv(N),
respectively.
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Table 2: Fractional atomic coordinates and isotropic or equivalent
isotropic displacement parameters (Å2).
Atom x y z Uiso*/Ueq
F1 0.02951(15) 0.37548(13) 0.38214(8) 0.0493(3)
F2 0.24872(13) 0.52419(9) 0.52189(9) 0.0385(2)
F3 0.07811(13) 0.35051(10) 0.53895(9) 0.0361(2)
F4 0.68301(14) 0.41825(10) 0.73814(8) 0.0408(3)
F5 0.46179(15) 0.24409(12) 0.72416(8) 0.0423(3)
F6 0.74099(17) 0.25665(13) 0.78058(8) 0.0521(3)
O1 0.27515(13) 0.17013(11) 0.11193(8) 0.0239(2)
H1O 0.1761(18) 0.1277(18) 0.1191(16) 0.036*
N1 0.39162(15) 0.30406(11) 0.52565(9) 0.0181(2)
N2 0.62889(15) 0.20936(11) 0.08180(9) 0.0185(2)
H1N 0.646(2) 0.1342(12) 0.0828(14) 0.022*
H2N 0.5280(16) 0.1840(16) 0.0269(11) 0.022*
C1 0.28884(17) 0.31996(12) 0.44213(10) 0.0171(2)
C2 0.29300(17) 0.27831(13) 0.33286(10) 0.0179(2)
H2 0.2188 0.2974 0.2774 0.021*
C3 0.40643(17) 0.20954(12) 0.30800(10) 0.0161(2)
C4 0.51298(17) 0.18144(12) 0.39366(10) 0.0158(2)
C5 0.62722(18) 0.10427(13) 0.37625(11) 0.0196(3)
H5 0.6313 0.0656 0.3039 0.024*
C6 0.7309(2) 0.08547(14) 0.46279(12) 0.0241(3)
H6 0.8045 0.0321 0.4498 0.029*
C7 0.7302(2) 0.14432(15) 0.57128(12) 0.0250(3)
H7 0.8063 0.1329 0.6309 0.030*
C8 0.62047(19) 0.21783(14) 0.59121(11) 0.0217(3)
C9 0.50491(17) 0.23564(12) 0.50262(10) 0.0168(2)
C10 0.16075(18) 0.39259(13) 0.47126(11) 0.0204(3)
C11 0.6245(2) 0.28366(17) 0.70762(12) 0.0311(3)
C12 0.42225(17) 0.16880(13) 0.19225(10) 0.0175(2)
H12 0.4292 0.0768 0.1715 0.021*
C13 0.59788(17) 0.26909(12) 0.18944(10) 0.0170(2)
H13 0.7034 0.2787 0.2510 0.020*
C14 0.7893(2) 0.29819(15) 0.06226(13) 0.0274(3)
H14A 0.7937 0.2554 −0.0127 0.033*
H14B 0.9041 0.3092 0.1161 0.033*
C15 0.7754(2) 0.43488(16) 0.07357(14) 0.0326(3)
H15A 0.6672 0.4251 0.0150 0.039*
H15B 0.8859 0.4935 0.0648 0.039*
C16 0.7578(2) 0.49892(15) 0.18635(13) 0.0314(3)
H16A 0.7470 0.5876 0.1929 0.038*
H16B 0.8686 0.5128 0.2449 0.038*
C17 0.5886(2) 0.40794(13) 0.20090(12) 0.0242(3)
H17A 0.5790 0.4497 0.2746 0.029*
H17B 0.4776 0.3988 0.1448 0.029*
F7 −0.08877(16) −0.11720(14) 0.25094(9) 0.0527(3)
F8 −0.2559(2) −0.25218(11) 0.08871(10) 0.0584(4)
F9 0.0247(2) −0.13334(18) 0.11646(14) 0.0802(5)
O2 −0.06241(14) 0.08467(11) 0.13035(10) 0.0345(3)
O3 −0.35082(13) −0.03455(10) 0.10914(8) 0.0235(2)
C18 −0.18437(19) −0.01618(14) 0.12451(10) 0.0213(3)
C19 −0.1253(3) −0.13127(19) 0.14389(14) 0.0367(4)
Comment
While originally developed as anti-malarial agents,
derivatives of mefloquine continue to be pharmacologically
relevant [7]. These studies are augmented by crystallographic
investigations which are motivated by reasons more than
the confirmation of molecular structure. Thus, two out of
approximately 30 crystal structures of mefloquine derivatives
[8] exhibit kryptoracemic behaviour [9]. The two unusual
examples were isolated during attempts at chiral resolu-
tion of racemic mefloquine (which has two chiral centres)
with different carboxylic acids. In the crystal of the first
example, two mefloquinium cations are related across a non-
crystallographic centre of inversion, with the charge balance
being provided by a pair of crystallographically independent
and chiral 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate
anions [10]. In the second example, it was proven not nec-
essary to have chiral carboxylate counter-ions to induce
kryptoracemic behaviour. This structure arises as a result
of incomplete substitution of chloride in the original salt
by 4-fluorobenzenesulfonate [11]. Here, the asymmetric unit
comprises a pair of pseudo-enantiomeric mefloquinium
cations with the charge balance being provided by equal
numbers of chloride and 4-fluorobenzenesulfonate anions
[11]. As a continuation of studies in this area [8, 10, 11], the
title salt, [C17H17F6N2O][C2F3O2], was characterised.
The molecular structures of the constituents of the
title salt are shown in the figure (50% probability dis-
placement ellipsoids). Proof that protonation occurred
during crystallisation is at least two-fold. Thus, the C—
O bond lengths of the carboxylate group, i.e. C18—O2,
O3 of 1.2320(18) and 1.2507(17) Å, are very similar. Also,
the pattern of hydrogen bonding and difference Fourier
maps confirm the presence of two protons on the N2 atom
of the piperidin-1-ium ring. The cation exhibits familiar
characteristics: an approximate L-shape with the dihedral
between the quinolinyl plane [r.m.s. deviation=0.0385 Å]
and the best plane through the piperidin-1-ium ring being
69.28(4)°. The hydroxyl-O1 and ammonium-N2 atoms
are orientated to the same side of the cation with the
O1—C12—C13—N2 torsion angle of −69.08(12)° indicating
a – syn-clinal relationship. This proximity enables the forma-
tion of an intramolecular ammonium-N+—H· · ·O(hydroxy)
hydrogen bond [N2—H2n· · ·O1: H2n· · ·O1= 2.500(14) Å,
N2· · ·O1= 2.8672(17) Å with angle at H2n= 105.8(10)°].
The most prominent feature of the molecular pack-
ing is the formation of supramolecular chains along
the a-axis. These are mediated by charge-assisted
hydrogen bonding. Each ammonium-N+—H atom con-
nects to a symmetry-related carboxylate-O3 atom via
ammonium-N+—H· · ·O−(carboxylate) hydrogen bonds
and through a centre of inversion generate eight-
membered {· · ·O· · ·HNH}2 synthons [N2—H1n· · ·O3i:
H1n· · ·O3i = 1.994(14) Å, N2· · ·O3i = 2.8580(17) Å
with angle at H1n= 166.5(15)° and N2—H2n· · ·O3ii:
H2n· · ·O3ii= 2.001(15) Å, N2· · ·O3ii= 2.7711(15)Å and angle
at H2n= 145.5(15)°; symmetry operations (i): 1−x, −y,
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1−z and (ii): −x, −y, −z]. The ensuing four-ion aggre-
gates just described are connected into the supramolecular
chain via charge-assisted hydroxyl-O—H· · ·O−(carboxylate)
hydrogen bonds [O1—H1o· · ·O2: H1o· · ·O2= 1.880(16) Å,
O1· · ·O2= 2.6856(17) Å with angle at H1o= 160.4(19)°].
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